Women with systemic lupus erythematosus (SLE) in the U.S. live on average 22 years less — and men an average of 12 fewer years — than members of the same sex among the public at large, according to new data from Stanford University. Leading causes of death for female…
With a $387,000 grant from the National Institutes of Health, researchers at the University of Houston are developing a new diagnostic test for lupus patients that uses saliva instead of the standard invasive methods. Led by Chandra Mohan, MD, PhD, and a Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering,…
New York City’s Hospital for Special Surgery (HSS) says its free telephone support line and education program for lupus patients has proven to be a valuable resource. HSS says its free LupusLine, now 29 years old, receives calls from around the world. People mostly know about it through their physicians,…
The European Commission has approved the new, self-administered and injectable formulation of  Benlysta (belimumab), by GSK, as an add-on therapy for certain adults with systemic lupus erythematosus (SLE). The approval applies to lupus patients with active autoantibody-positive disease and high disease activity in spite of standard therapy.
EMD Serono‘s atacicept can effectively reduce disease activity among lupus patients with high disease activity at baseline, according to new data from the Phase 2b ADDRESS II trial. The study, “Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus Starting with High Disease Activity in a 24-Week,…
GlaxoSmithKline’s Benlysta reduced lupus patients’ need for higher doses of corticosteroids, a therapy that is beneficial but causes long-term organ damage, an additional analysis of Phase 3 clinical trial results shows. In addition, a combination of Benlysta and corticosteroids reduced patients’ organ damage more than corticosteroids alone over five years, two extensions…
Obese women with systemic lupus erythematosus (SLE) have a poorer quality of life and suffer more symptoms than women of normal weight, according to new research presented at the 2017 ACR/ARHP Annual Meeting in San Diego. The study, “Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic…
Janssen announced that its investigational antibody Stelara (ustekinumab) showed positive results in a Phase 2 trial as a therapy for patients with systemic lupus erythematosus (SLE). Based on these results, the company said it would further test Stelara in a Phase 3 development program planned for 2018. The study, “Efficacy and…
Results from a 24-week Phase 2b study show that atacicept treatment is safe and reduces disease activity and severe flare in systemic lupus erythematosus (SLE) patients, particularly in those with high disease activity or serologically active disease. Results of the ADDRESS II trial (NCT01972568) were published in the study, “…
Results of a Phase 3 clinical trial of blisibimod, by Anthera Pharmaceuticals, found that treatment significantly reduces proteinuria — excess proteins in the urine — in patients with systemic lupus erythematous (SLE). Like many B-cell mediated autoimmune diseases, lupus is associated with elevated levels of B-cell activating factor (BAFF). Blisibimod is…